Recent

% | $
Quotes you view appear here for quick access.

Alkermes plc Message Board

stuey.olsen 1 post  |  Last Activity: Jan 12, 2015 3:09 AM Member since: May 19, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • stuey.olsen by stuey.olsen Jan 12, 2015 3:09 AM Flag

    See 5/6/14 IOS Press - Google "Exenatide Parkinson's IOS" and Google "Exanetide Alzheimer's"

    No recent updates- but what is ALKS royalty on Bydureon? (Bydureon = Exanetide)
    From IOS- A follow-up study of patients with Parkinson’s disease (PD) who participated in an earlier “proof of concept” clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. These data provide strong encouragement for the further study

    A follow-up study of patients with Parkinson’s disease (PD) who participated in an earlier “proof of concept” clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers in the Journal of Parkinson’s Disease.

    Several recent discoveries have highlighted common cellular pathways that potentially relate neurodegenerative processes with abnormal mitochondrial function and abnormal glucose metabolism.

    Exenatide, a glucagon-like peptide-1 agonist (GLP-1 agonist) medication marketed as Byetta® and Bydureon® and used in the treatment of insulin resistance in patients with Type 2 diabetes, has been proposed as a disease modifying drug in PD

ALKS
60.94-0.03(-0.05%)Apr 1 4:00 PMEDT